A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar

Background: This study assessed the evolution of COVID-19 severity and fatality by utilizing rigorous and standardized criteria that were consistently applied throughout the pandemic in Qatar. Methods: A national cohort study was conducted on Qataris, using data on COVID-19 acute-care and ICU hospitalizations, as well as severe, critical, and fatal COVID-19 cases classified according to the World Health Organization criteria. Results: The cumulative incidence of severe, critical, or fatal COVID-19 after 3.14 years of follow-up was 0.45% (95% CI: 0.43-0.47%). The incidence rate for severe, critical, or fatal COVID-19 throughout the pandemic was 1.43 (95% CI: 1.35-1.50) per 1,000 person-years. In the pre-omicron phase, first omicron wave, and combined phases, it was 2.01 (95% CI: 1.90-2.13), 3.70 (95% CI: 3.25-4.22), and 2.18 (95% CI: 2.07-2.30) per 1,000 person-years, respectively. The post-first omicron phase saw a drastic drop to 0.10 (95% CI: 0.08-0.14) per 1,000 person-years, a 95.4% reduction. Among all severe, critical, and fatal cases, 99.5% occurred during the primary infection. The cumulative incidence of fatal COVID-19 was 0.042% (95% CI: 0.036-0.050%), with an incidence rate of 0.13 (95% CI: 0.11-0.16) per 1,000 person-years. In the post-first omicron phase, the incidence rate of fatal COVID-19 decreased by 90.0% compared to earlier stages. Both severity and fatality exhibited an exponential increase with age and a linear increase with the number of coexisting conditions. Conclusions: The conclusion of the first omicron wave was a turning point in the severity of the pandemic. While vaccination and enhanced case management reduced severity gradually, the rapid accumulation of natural immunity during the initial omicron wave appears to have played the crucial role in driving this shift in severity.

[1]  L. Abu-Raddad,et al.  All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic , 2023, BMJ Global Health.

[2]  A. Sodickson,et al.  Prevalence of Pneumonia Among Patients Who Died with COVID-19 Infection in Ancestral Versus Omicron Variant Eras , 2023, Academic Radiology.

[3]  Gheyath K Nasrallah,et al.  Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study , 2023, medRxiv.

[4]  Gheyath K Nasrallah,et al.  Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infections , 2023, medRxiv.

[5]  Gheyath K Nasrallah,et al.  Bivalent mRNA-1273.214 vaccine effectiveness in Qatar , 2023, medRxiv.

[6]  Gheyath K Nasrallah,et al.  Short- and longer-term all-cause mortality among SARS-CoV-2- infected persons and the pull-forward phenomenon in Qatar , 2023, medRxiv.

[7]  Gheyath K Nasrallah,et al.  Protection against Reinfection with the Omicron BA.2.75 Subvariant , 2023, The New England journal of medicine.

[8]  J. Wakefield,et al.  The WHO estimates of excess mortality associated with the COVID-19 pandemic , 2022, Nature.

[9]  Gheyath K Nasrallah,et al.  Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study , 2022, The Lancet Infectious Diseases.

[10]  Gheyath K Nasrallah,et al.  Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants , 2022, The New England journal of medicine.

[11]  L. Abu-Raddad,et al.  COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status. , 2022, JAMA internal medicine.

[12]  Shu-Xia Li,et al.  Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state , 2022, The Lancet Infectious Diseases.

[13]  L. Abu-Raddad,et al.  COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar , 2022, Journal of global health.

[14]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[15]  J. Malek,et al.  Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance , 2022, Environmental Technology & Innovation.

[16]  L. Abu-Raddad,et al.  Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization , 2022, Vaccine.

[17]  L. Abu-Raddad,et al.  Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar , 2022, International Journal of Infectious Diseases.

[18]  Gheyath K Nasrallah,et al.  Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.

[19]  Gheyath K Nasrallah,et al.  Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.

[20]  Gheyath K Nasrallah,et al.  Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections , 2022, medRxiv.

[21]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[22]  Gheyath K Nasrallah,et al.  Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.

[23]  Gheyath K Nasrallah,et al.  Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.

[24]  S. Pilz,et al.  SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity , 2022, Environmental Research.

[25]  L. Abu-Raddad,et al.  Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar , 2022, The New England journal of medicine.

[26]  L. Abu-Raddad,et al.  Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.

[27]  Gheyath K Nasrallah,et al.  Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study , 2021, PLoS medicine.

[28]  L. Abu-Raddad,et al.  Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections , 2021, The New England journal of medicine.

[29]  L. Abu-Raddad,et al.  BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.

[30]  L. Abu-Raddad,et al.  SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar , 2021, Scientific Reports.

[31]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[32]  L. Abu-Raddad,et al.  Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar , 2021, medRxiv.

[33]  Gheyath K Nasrallah,et al.  mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar , 2021, Nature Medicine.

[34]  J. Malek,et al.  One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar , 2021, Frontiers in Cellular and Infection Microbiology.

[35]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[36]  Gheyath K Nasrallah,et al.  SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar , 2021, Open forum infectious diseases.

[37]  L. Abu-Raddad,et al.  Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar , 2021, Emerging infectious diseases.

[38]  Gheyath K Nasrallah,et al.  SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy , 2021, EClinicalMedicine.

[39]  C. Vogels Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern v3 , 2021 .

[40]  Oluwaseun O. Ogunbiyi,et al.  COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar , 2021, Science of The Total Environment.

[41]  L. Abu-Raddad,et al.  Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020 , 2021, Global Epidemiology.

[42]  L. Summers,et al.  The COVID-19 Pandemic and the $16 Trillion Virus. , 2020, JAMA.

[43]  R. Bertollini,et al.  Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic , 2020, Scientific Reports.

[44]  C. Y. Li,et al.  A review of the healthy worker effect in occupational epidemiology. , 1999, Occupational medicine.

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .